These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29630530)

  • 1. Bioresorbable everolimus-eluting vascular scaffold for patients presenting with non STelevation-acute coronary syndrome: A three-years follow-up1.
    Anadol R; Dimitriadis Z; Polimeni A; Wendling F; Gönner S; Ullrich H; Lorenz L; Weissner M; Munzel T; Gori T
    Clin Hemorheol Microcirc; 2018; 69(1-2):3-8. PubMed ID: 29630530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry.
    Imori Y; D'Ascenzo F; Gori T; Münzel T; Fabrizio U; Campo G; Cerrato E; Napp LC; Iannaccone M; Ghadri JR; Kazemian E; Binder RK; Jaguszewski M; Csordas A; Capasso P; Biscaglia S; Conrotto F; Varbella F; Garbo R; Gaita F; Erne P; Lüscher TF; Moretti C; Frangieh AH; Templin C
    Cardiol J; 2016; 23(4):374-83. PubMed ID: 27515481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.
    Capodanno D; Gori T; Nef H; Latib A; Mehilli J; Lesiak M; Caramanno G; Naber C; Di Mario C; Colombo A; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Pyxaras S; Mattesini A; Naganuma T; Münzel T; Tamburino C
    EuroIntervention; 2015 Feb; 10(10):1144-53. PubMed ID: 25042421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-Analysis Comparing Outcomes After Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients with Acute Coronary Syndromes.
    De Rosa R; Silverio A; Varricchio A; De Luca G; Di Maio M; Radano I; Belmonte M; De Angelis MC; Moscarella E; Citro R; Piscione F; Galasso G
    Am J Cardiol; 2018 Jul; 122(1):61-68. PubMed ID: 29699747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
    Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
    Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
    Naganuma T; Kawamoto H; Panoulas VF; Latib A; Tanaka A; Mitomo S; Ruparelia N; Jabbour RJ; Chieffo A; Carlino M; Montorfano M; Colombo A
    Int J Cardiol; 2017 Nov; 246():26-31. PubMed ID: 28867010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
    Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results.
    Goktekin O; Yamac AH; Latib A; Tastan A; Panoulas VF; Sato K; Erdogan E; Uyarel H; Shah I; Colombo A
    J Invasive Cardiol; 2015 Oct; 27(10):461-6. PubMed ID: 26429848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry.
    Ortega-Paz L; Capodanno D; Giacchi G; Gori T; Nef H; Latib A; Caramanno G; Di Mario C; Naber C; Lesiak M; Capranzano P; Wiebe J; Mehilli J; Araszkiewicz A; Pyxaras S; Mattesini A; Geraci S; Naganuma T; Colombo A; Münzel T; Sabaté M; Tamburino C; Brugaletta S
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):812-818. PubMed ID: 27515568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Two-year results from the German-Austrian ABSORB registry.
    Tröbs M; Achenbach S; Nef HM; Gori T; Naber C; Neumann T; Richardt G; Schmermund A; Wöhrle J; Zahn R; Hamm CW;
    Catheter Cardiovasc Interv; 2021 Oct; 98(4):E564-E570. PubMed ID: 34137482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation.
    Wiebe J; Dörr O; Liebetrau C; Bauer T; Wilkens E; Ilstad H; Boeder N; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1144-1151. PubMed ID: 28134094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.